See more : Hillenbrand, Inc. (HI) Income Statement Analysis – Financial Results
Complete financial analysis of Dynavax Technologies Corporation (DVAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dynavax Technologies Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Glow Lifetech Corp. (GLOW.CN) Income Statement Analysis – Financial Results
- SG MART LIMITED (SGMART.BO) Income Statement Analysis – Financial Results
- Suntront Technology Co., Ltd. (300259.SZ) Income Statement Analysis – Financial Results
- Energizer Holdings, Inc. (ENR) Income Statement Analysis – Financial Results
- CardioComm Solutions, Inc. (EKGGF) Income Statement Analysis – Financial Results
Dynavax Technologies Corporation (DVAX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.dynavax.com
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 232.28M | 722.68M | 439.44M | 46.55M | 35.22M | 8.20M | 327.00K | 11.04M | 4.05M | 11.03M | 11.25M | 9.71M | 21.61M | 23.95M | 40.32M | 37.09M | 14.09M | 4.85M | 14.66M | 14.81M | 826.00K | 1.43M | 2.36M | 0.00 |
| Cost of Revenue | 50.17M | 262.15M | 173.57M | 13.91M | 19.39M | 21.80M | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 299.00K | 980.00K | 980.00K | 980.00K | 1.00M | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 182.12M | 460.53M | 265.87M | 32.64M | 15.83M | -13.60M | -867.00K | 11.04M | 4.05M | 11.03M | 11.25M | 9.71M | 21.32M | 22.97M | 39.34M | 36.11M | 13.09M | 4.15M | 14.66M | 14.81M | 826.00K | 1.43M | 2.36M | 0.00 |
| Gross Profit Ratio | 78.40% | 63.73% | 60.50% | 70.12% | 44.95% | -165.87% | -265.14% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 98.62% | 95.91% | 97.57% | 97.36% | 92.88% | 85.60% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 54.89M | 46.60M | 32.23M | 28.61M | 62.33M | 74.95M | 64.99M | 84.49M | 86.94M | 84.58M | 50.87M | 49.15M | 51.32M | 53.68M | 38.71M | 44.77M | 65.89M | 50.12M | 27.89M | 23.13M | 14.38M | 15.97M | 17.36M | 8.27M |
| General & Administrative | 152.95M | 131.41M | 100.16M | 79.26M | 48.72M | 64.77M | 27.37M | 37.26M | 22.18M | 17.76M | 26.87M | 28.16M | 17.57M | 16.88M | 15.75M | 15.46M | 18.29M | 14.84M | 9.26M | 8.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 24.76M | 26.27M | 31.76M | 7.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 152.95M | 131.41M | 100.16M | 79.26M | 74.99M | 64.77M | 27.37M | 37.26M | 22.18M | 17.76M | 26.87M | 28.16M | 17.57M | 16.88M | 15.75M | 15.46M | 18.29M | 14.84M | 9.26M | 8.54M | 4.21M | 4.12M | 4.53M | 3.45M |
| Other Expenses | 11.31M | 7.80M | 8.66M | 6.81M | 3.35M | -70.00K | -486.00K | -2.49M | 317.00K | 433.00K | -348.00K | -293.00K | 299.00K | 980.00K | 980.00K | 980.00K | 1.00M | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 219.15M | 178.01M | 132.38M | 107.86M | 137.32M | 139.72M | 93.55M | 121.75M | 109.12M | 102.34M | 77.74M | 77.31M | 69.19M | 71.54M | 55.43M | 61.21M | 85.19M | 65.65M | 37.15M | 31.67M | 18.59M | 20.09M | 21.89M | 11.72M |
| Cost & Expenses | 269.31M | 440.16M | 305.96M | 121.77M | 156.71M | 161.52M | 93.55M | 121.75M | 109.12M | 102.34M | 77.74M | 77.31M | 69.19M | 71.54M | 55.43M | 61.21M | 85.19M | 65.65M | 37.15M | 31.67M | 18.59M | 20.09M | 21.89M | 11.72M |
| Interest Income | 31.99M | 7.91M | 140.00K | 1.26M | 3.37M | 3.83M | 1.34M | 755.00K | 205.00K | 191.00K | 116.00K | 291.00K | 103.00K | 85.00K | 112.00K | 1.74M | 4.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.76M | 6.73M | 11.18M | 19.06M | 16.98M | 9.34M | 0.00 | 0.00 | 572.00K | 35.00K | 0.00 | 2.35M | 1.96M | 1.65M | 124.00K | 9.16M | 1.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.28M | 6.67M | 7.01M | 9.34M | 21.53M | 14.48M | 4.44M | 2.26M | 1.37M | 1.40M | 1.33M | 1.21M | 1.60M | 2.40M | 2.84M | 2.83M | 632.00K | 1.53M | 3.13M | 3.27M | 576.00K | 678.00K | 0.00 | -2.05M |
| EBITDA | 9.67M | 307.70M | 95.71M | -46.84M | -114.09M | -135.08M | -90.72M | -110.19M | -104.86M | -89.28M | -65.39M | -66.39M | -45.04M | -53.26M | -12.17M | -21.29M | -71.09M | -60.67M | -19.36M | -15.44M | -17.19M | -17.98M | -19.53M | -11.72M |
| EBITDA Ratio | 4.16% | 41.27% | 32.38% | -144.26% | -325.87% | -1,824.36% | -27,292.05% | -1,002.51% | -2,581.51% | -822.04% | -579.16% | -695.88% | -216.57% | -154.67% | -30.45% | -70.87% | -497.32% | -1,136.60% | -132.09% | -91.73% | -2,080.87% | -1,260.06% | -827.94% | 0.00% |
| Operating Income | -37.03M | 283.52M | 134.49M | -75.22M | -121.49M | -153.32M | -96.01M | -110.71M | -105.07M | -91.31M | -66.49M | -67.60M | -47.58M | -47.59M | -15.12M | -24.12M | -71.09M | -64.98M | -22.49M | -16.86M | -17.76M | -18.66M | -19.53M | -9.66M |
| Operating Income Ratio | -15.94% | 39.23% | 30.60% | -161.59% | -344.95% | -1,870.20% | -29,359.33% | -1,002.51% | -2,594.40% | -827.69% | -590.95% | -695.86% | -220.12% | -198.70% | -37.49% | -65.02% | -504.45% | -1,340.68% | -153.46% | -113.83% | -2,150.61% | -1,307.57% | -827.94% | 0.00% |
| Total Other Income/Expenses | 32.66M | 10.78M | -56.97M | -6.87M | -17.76M | -5.58M | 851.00K | -1.74M | -1.72M | 589.00K | -232.00K | -2.35M | -1.02M | -9.72M | -12.00K | -2.42M | 2.45M | 3.19M | 1.94M | 889.00K | -274.00K | 0.00 | 19.53M | 0.00 |
| Income Before Tax | -4.37M | 294.30M | 77.52M | -75.24M | -152.60M | -158.90M | -95.15M | -112.44M | -106.79M | -90.72M | -66.72M | -69.95M | -48.60M | -57.31M | -30.57M | -20.83M | -59.97M | -52.05M | -20.56M | -15.97M | -18.04M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -1.88% | 40.72% | 17.64% | -161.63% | -433.29% | -1,938.27% | -29,099.08% | -1,018.24% | -2,636.89% | -822.35% | -593.01% | -720.08% | -224.84% | -239.28% | -75.81% | -56.15% | -425.54% | -1,073.90% | -140.26% | -107.82% | -2,183.78% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.02M | 1.14M | 808.00K | 16.54M | -1.20M | 3.76M | 1.45M | -3.01M | -476.00K | -936.00K | -116.00K | 851.00K | 1.02M | 9.72M | 0.00 | -3.29M | 372.00K | -8.75M | 0.00 | 0.00 | -686.00K | -621.00K | 18.41M | 17.06M |
| Net Income | -6.39M | 293.16M | 76.71M | -91.78M | -151.40M | -158.90M | -95.15M | -112.44M | -106.79M | -90.72M | -66.72M | -69.95M | -48.60M | -57.31M | -30.57M | -20.83M | -59.97M | -52.05M | -20.56M | -15.97M | -17.35M | -18.04M | -18.41M | -26.72M |
| Net Income Ratio | -2.75% | 40.56% | 17.46% | -197.15% | -429.87% | -1,938.27% | -29,099.08% | -1,018.24% | -2,636.89% | -822.35% | -593.01% | -720.08% | -224.84% | -239.28% | -75.81% | -56.15% | -425.54% | -1,073.90% | -140.26% | -107.82% | -2,100.73% | -1,264.05% | -780.50% | 0.00% |
| EPS | -0.05 | 2.32 | 0.62 | -0.91 | -2.10 | -2.55 | -1.81 | -2.92 | -3.25 | -3.45 | -3.40 | -4.10 | -3.88 | -6.95 | -7.57 | -5.23 | -15.09 | -16.10 | -7.93 | -7.54 | -96.88 | -106.04 | -122.91 | -225.90 |
| EPS Diluted | -0.05 | 1.97 | 0.54 | -0.91 | -2.10 | -2.55 | -1.81 | -2.92 | -3.25 | -3.45 | -3.40 | -4.10 | -3.88 | -6.95 | -7.57 | -5.23 | -15.09 | -16.10 | -7.93 | -7.54 | -96.24 | -106.04 | -122.91 | -225.90 |
| Weighted Avg Shares Out | 128.73M | 126.40M | 116.26M | 100.75M | 72.02M | 62.36M | 52.61M | 38.51M | 32.88M | 26.29M | 19.63M | 17.05M | 12.51M | 8.25M | 4.04M | 3.98M | 3.97M | 3.23M | 2.59M | 2.12M | 179.10K | 170.10K | 149.80K | 118.30K |
| Weighted Avg Shares Out (Dil) | 128.73M | 150.80M | 133.01M | 100.75M | 72.02M | 62.36M | 52.61M | 38.51M | 32.88M | 26.29M | 19.63M | 17.05M | 12.51M | 8.25M | 4.04M | 3.98M | 3.97M | 3.23M | 2.59M | 2.12M | 180.30K | 170.10K | 149.80K | 118.30K |
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability,...
Dynavax to Present at Upcoming Investor Conferences
EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 44th...
Natixis Advisors L.P. Buys 1,804 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)
Natixis Advisors L.P. boosted its stake in Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 10.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,058 shares of the biopharmaceutical...
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
The U.S. Food and Drug Administration has declined to approve the expanded use of Dynavax Technologies' hepatitis B vaccine in patients undergoing hemodialysis, the company said on Tuesday.
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
EMERYVILLE, Calif. , May 14, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted] regimen for adults on hemodialysis.
Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen -...
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Dynavax Technologies (DVAX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.19 per share a year ago.
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
HEPLISAV-B ® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024 Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Announces U.S. FDA clearance of IND application to initiate Phase...
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
EMERYVILLE, Calif. , April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets...
Dynavax Technologies: Still A Believer
Dynavax's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav potential sales reaching $400 million by FY27. Dynavax's stock...
Source: https://incomestatements.info
Category: Stock Reports